Kobayashi Pharmaceutical Co Ltd
TSE:4967
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 875
6 863
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Kobayashi Pharmaceutical Co Ltd
Kobayashi Pharmaceutical Co Ltd
Cash Paid for Dividends
Kobayashi Pharmaceutical Co Ltd
Cash Paid for Dividends Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Paid for Dividends | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kobayashi Pharmaceutical Co Ltd
TSE:4967
|
Cash Paid for Dividends
-¥7.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Shiseido Co Ltd
TSE:4911
|
Cash Paid for Dividends
-¥24.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-12%
|
|
|
Rohto Pharmaceutical Co Ltd
TSE:4527
|
Cash Paid for Dividends
-¥6.2B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
|
Kao Corp
TSE:4452
|
Cash Paid for Dividends
-¥70.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-8%
|
|
|
Kose Corp
TSE:4922
|
Cash Paid for Dividends
-¥8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-11%
|
|
|
F
|
Fancl Corp
TSE:4921
|
Cash Paid for Dividends
-¥4.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
Kobayashi Pharmaceutical Co Ltd
Glance View
In the bustling landscape of Japanese business, Kobayashi Pharmaceutical Co., Ltd. stands as an epitome of innovation and tradition. Founded in 1886, this company, steeped in history, has consistently demonstrated a knack for transforming simple consumer needs into thriving business opportunities. Core to its operations is the development, manufacturing, and marketing of consumer healthcare products that subtly blend pharmaceutical expertise with daily convenience. This approach has allowed Kobayashi Pharmaceutical to carve out a distinctive niche, particularly in over-the-counter (OTC) health and personal care products. The company's vast array of products is remarkably diverse, ranging from cooling gel sheets for fevers to herbal medicinal drinks, each crafted with an understanding of consumer pain points and a commitment to well-being. What sets Kobayashi apart in the competitive market is its strategic focus on niche products that serve unmet needs. This laser-sharp business model does more than just bolster its domestic market; it drives its global expansion into key markets in Asia, North America, and Europe. The company's profitability hinges not just on innovation but also on its agile response to the shifting preferences of health-conscious consumers. Driven by a mission to deliver "small but valuable products," Kobayashi’s nimble approach, coupled with an impressive R&D focus, ensures that it remains at the forefront of both consumer satisfaction and shareholder value. Much like a well-crafted Japanese garden, every part of Kobayashi's operation is meticulously designed to function harmoniously, making it a standout player in the global consumer healthcare industry.
See Also
What is Kobayashi Pharmaceutical Co Ltd's Cash Paid for Dividends?
Cash Paid for Dividends
-7.6B
JPY
Based on the financial report for Sep 30, 2024, Kobayashi Pharmaceutical Co Ltd's Cash Paid for Dividends amounts to -7.6B JPY.
What is Kobayashi Pharmaceutical Co Ltd's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 10Y
-8%
Over the last year, the Cash Paid for Dividends growth was -10%. The average annual Cash Paid for Dividends growth rates for Kobayashi Pharmaceutical Co Ltd have been -8% over the past three years , -8% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet
